"won't Dr Ray make sure he gives data on eGFR and other bio markers (and independent risk factors) that are supportive of Apabetalone re CVD, effectively shedding light on how the CKD and cognition sub studies panned out?"

All I am definitively expecting to be presented at AHA and published are the cardiovascular related findings. I would be happy to be wrong and would be ecstatic if the CKD sub-study results for eGFR change, etc. are presented at AHA. Now that I think about it, the three ASN abstracts and no ASN late breaker for CKD sub-study are a perfect set up for CKD data to be announced at AHA. Very interesting.....

BDAZ